Compare ALGN & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALGN | EXEL |
|---|---|---|
| Founded | 1997 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 11.1B |
| IPO Year | N/A | 2000 |
| Metric | ALGN | EXEL |
|---|---|---|
| Price | $147.44 | $43.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 24 |
| Target Price | ★ $190.50 | $44.73 |
| AVG Volume (30 Days) | 1.5M | ★ 2.8M |
| Earning Date | 10-29-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.55 |
| EPS | ★ 5.16 | 2.38 |
| Revenue | ★ $3,982,622,000.00 | $2,288,218,000.00 |
| Revenue This Year | $2.48 | $9.14 |
| Revenue Next Year | $3.44 | $12.51 |
| P/E Ratio | $28.42 | ★ $18.28 |
| Revenue Growth | 0.56 | ★ 9.93 |
| 52 Week Low | $122.00 | $31.90 |
| 52 Week High | $246.19 | $49.62 |
| Indicator | ALGN | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 63.15 | 59.14 |
| Support Level | $132.64 | $41.65 |
| Resistance Level | $152.99 | $44.91 |
| Average True Range (ATR) | 4.83 | 1.19 |
| MACD | 1.06 | 0.12 |
| Stochastic Oscillator | 72.72 | 57.88 |
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.